Benzinga | Dec 9, 2020 07:01AM EST

Medicenna Announces Oral Presentation at the 2nd Annual Glioblastoma Drug Development Summit

Medicenna Therapeutics Corp. ("Medicenna" or "the Company") (NASDAQ:MDNA, TSX:MDNA), a clinical stage immuno-oncology company, today announced that Dr. Fahar Merchant, President and CEO of Medicenna and Dr. Ruthie Davi of Acorn AI will be presenting an oral presentation as part of the 2nd Annual Glioblastoma Drug Development Summit, which is being held virtually today through December 10, 2020.

The presentation will include updated data from the Phase 2b trial (MDNA55-05) evaluating MDNA55 in recurrent glioblastoma (rGBM) patients, as well as an overview of a planned MDNA55 Phase 3 registration trial. Following the End of Phase 2 Meeting, the United States Food and Drug Administration (FDA) has agreed that this registration trial can utilize an innovative open-label hybrid design that allows use of matched external control for two-thirds of the trial's control arm. Such a design should provide the opportunity to accelerate trial timelines and reduce costs when compared with a traditional randomized control trial.

Details on the oral presentation are shown below:

Title: MDNA55, an IL4-Guided Toxin in Recurrent GBM: Phase 2b Results & Use of an External Control Arm in a Registration Trial

Session Name: Immuno-oncology & Therapy

Presentation Date & Time: Today, December 9, 2020 at 10:50 AM ET

Slides from the presentation will be posted to the "Events and Presentations" page of Medicenna's website following the conference.